Author(s):
Pramod Kumar A., Dharini Boopathi, Rahamthulla Shaik, Srikanth Naik Bhukya, Mighty goldstone Alladi, Bala Pravalika Mallavarapu, Deepalakshmi Mani
Email(s):
deepapharmacy@jssuni.edu.in
DOI:
10.52711/0974-360X.2024.00533 
Address:
Pramod Kumar A.1, Dharini Boopathi2, Rahamthulla Shaik3, Srikanth Naik Bhukya3, Mighty goldstone Alladi3, Bala Pravalika Mallavarapu3, Deepalakshmi Mani4*
1Department of Pharmacy Practice, Faculty of Pharmacy, MS Ramaiah College of Pharmacy Ramaiah University of Applied Sciences, Bangalore - 560054, Karnataka, India.
2Senior Pharmacovigilance Associate - Adverse Reaction Monitoring Centre, Karpagam Faculty of Medical Science and Research, Coimbatore, India.
3Department of Pharmacy Practice, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Andhra Pradesh, India.
4Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 7,
Year - 2024
ABSTRACT:
Universal immunization programme monitors the efficacy and safety data related to vaccines via Adverse Events Following Immunization Secretariat and Immunization Technical Support Unit. Despite, there is a large data about AEFI; there exists a least data regarding the assessment of observed AEFIs. The objective of the study is to identify, report and assess the AEFIs for causality, severity, predictability and preventability. The prospective and observational study enrolled eligible subjects of age 0-14 weeks receiving vaccination from the immunization center at NRI general and multi-specialty hospital, Guntur, Andhra Pradesh. The study participants were monitored for 30 minutes post-vaccination and a telephonic survey was conducted after one week to identify AEFIs. All the AEFIs were assessed for causality, severity, predictability, preventability using appropriate scales. The incidence rate of observed AEFIs after Pentavalent-I dose was found to be 92.26. The most frequently observed AEFI was fever (26.62%) followed by Erythema (28.08%), swelling (25.21%), crying for 24 hrs (19.33%) and crying for 48 hr (3.33%). Upon causality assessment all the AEFIs were found to be consistent and vaccine product related reactions. 51.23% of AEFIs were found to be mild and rest was moderate in their severity. All the AEFIs were found to be predictable and 26.62% of AEFIs were preventable. Incidence rates of AEFIs were much higher than similar, previous studies. There existsno immunization-error related, vaccine-quality related, immunization-anxiety related reactions in our study. AEFI identification and reporting should be made mandatory at all clinics to know the incidence rates and severity among different population and to predict and prevent the severe AEFIs.
Cite this article:
Pramod Kumar A., Dharini Boopathi, Rahamthulla Shaik, Srikanth Naik Bhukya, Mighty goldstone Alladi, Bala Pravalika Mallavarapu, Deepalakshmi Mani. Identification and Reporting of Adverse events following Immunization – A Prospective and Observational Study. Research Journal of Pharmacy and Technology. 2024; 17(7):3409-4. doi: 10.52711/0974-360X.2024.00533
Cite(Electronic):
Pramod Kumar A., Dharini Boopathi, Rahamthulla Shaik, Srikanth Naik Bhukya, Mighty goldstone Alladi, Bala Pravalika Mallavarapu, Deepalakshmi Mani. Identification and Reporting of Adverse events following Immunization – A Prospective and Observational Study. Research Journal of Pharmacy and Technology. 2024; 17(7):3409-4. doi: 10.52711/0974-360X.2024.00533 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-7-66
REFERENCES:
1. Center for Disease control and Prevention (CDC), Vaccines and Immunization: The Basics, Reviewed 2018, available at https://www.cdc.gov/vaccines/vac-gen/imz-basics.html.
2. U. S. Department of Health and Human Services, Vaccines for infants, children and teens, Vaccines. gov, Reviewed 2020, available at https://www.vaccines.gov/who_and_when.
3. U. S. Department of Health and Human Services, Vaccine Basics –Vaccine Ingredients, reviewed 2020, available at https://www.vaccines.gov/basics/vaccine_ingredients.
4. World Health Organization (WHO), Vaccine Safety, The Global Vaccine Safety Initiative – AEFIs, available at https://www.who.int/vaccine_safety/initiative/detection/AEFI/en/.
5. U. S. Department of Health and Human Services, Vaccine Basics –Vaccine Ingredients, reviewed 2020, available at https://www.vaccines.gov/basics/vaccine_ingredients.
6. World Health Organization (WHO), Classification of Adverse Events Following Immunization (AEFI), available at https://vaccine-safety-training.org/classification-of-aefis.html.
7. Keja K., et al. Expanded programme on immunization. World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales. 1988; 41(2): 59-63.
8. U. S. Department of Health and Human Services, Vaccines for infants, children and teens, Vaccines. gov, reviewed 2020, available at https://www.vaccines.gov/who_and_when.
9. National Health Mission (NHM), Immunization, reviewed on 2020, available at https://nhm.gov.in/index1.php?lang=1&level=2&sublinkid=824&lid=220.
10. Joshi J., et al. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India. Indian Journal of Pediatrics. 2018; 85(2): 139-148. doi:10.1007/s12098-017-2532-9.
11. Joshi ND., et al. Pattern of adverse events following immunization in an Indian teaching hospital International Journal of Medical Science and Public Health 2013; Jan 1; 2(1): 62-8.
12. Aherkar R., et al. Study of the pattern of adverse events following immunization of children in a tertiary care hospital. International Journal of Basic & Clinical Pharmacology. 2016; May: 609-15.
13. Khazaei S., et al. Adverse events following immunization (AEFI) in children under 7-year of Age during 2014 in Hamedan Province, Iran. International Journal of Pediatrics. 2016; 4(5): 1697-703.
14. Carrasco-Garrido P., et al. Incidence of adverse reactions to vaccines in a paediatric population. Clinical Drug Investigation. 2004; Aug; 24: 457-63. doi:10.2165/00044011-200424080-00004
15. Zhou W., et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001 [published correction appears in MMWR Morb Mortal Wkly Rep. 2003; Feb 14; 52(06): 113]. Morbidity and mortality weekly report. Surveillance Summaries (Washington, D.C. : 2002). 2003; 52(1): 1-24.
16. Kar S., et al. Adverse events following immunization of infants–an experience at an immunization clinic of a tertiary care hospital in Odisha, India.
17. Sebastian J., et al. Active surveillance of adverse events following immunization (AEFI): a prospective 3-year vaccine safety study. Therapeutic Advances in Vaccines and Immunotherapy. 2019; Nov; 7: 2515135519889000. doi:10.1177/2515135519889000
18. Singh AK., et al. Causality assessment of serious and severe adverse events following immunization in India: a 4-year practical experience. Expert Review of Vaccines. 2018; Jun 3; 17(6): 555-62. S. doi:10.1080/14760584.2018.1484285.
19. Mansoor O, Pillans PI. Vaccine adverse events reported in New Zealand 1990-5. The New Zealand Medical Journal. 1997; Jul 1; 110(1048): 270-2.
20. Mahajan D., et al. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Communicable Diseases Intelligence Quarterly Report. 2010; Sep; 34(3): 259-76.